BioXcel Therapeutics (BTAI) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

BTAI BioXcel Therapeutics

Watchlist

0.580
+0.012+2.06%

Close Nov 18 16:00 ET

24.79MMarket Cap-284P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

BofA Securities Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating
Moomoo NewsNov 15 09:33 ET · Ratings
Bank of America Securities Reaffirms Their Buy Rating on Bioxcel Therapeutics (BTAI)
TipRanksNov 15 09:25 ET · Ratings
BioXcel Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Revenue Results.
BenzingaNov 14 15:17 ET
BioXcel Therapeutics | 10-Q: Q3 2024 Earnings Report
SECNov 14 09:17 ET · Announcements
BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript Summary
moomoo AINov 14 09:16 ET · Conference Call
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates
Zacks Nov 14 07:25 ET

Comments

Jaguar8

Nov 12 06:01

NEWS

$BioXcel Therapeutics (BTAI.US)$
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia
First patient randomized in SERENITY At-Home trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia
Received FDA feedback on protocol for TRANQUILITY In-Care trial of BXCL501 for agitation associated with Alzheimer's dementia (AAD)
Estimated 140 ...

Trytosaveabit

Oct 15 06:21

Update!

$BioXcel Therapeutics (BTAI.US)$ BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of Bxcl501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Jaguar8

Sep 5 06:58

NEWS

$BioXcel Therapeutics (BTAI.US)$
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

WJJG

Jul 16 06:14

Good news! 90% increase Q over Q

$BioXcel Therapeutics (BTAI.US)$ …The Company expects unaudited revenue of approximately $1.1 million for the three months ended June 30, 2024, representing an increase of approximately 90% quarter over quarter and approximately 141% compared to the same period in 2023. Revenue growth was driven by an increase in contracting with psychiatric care clinics and behavioral health facilities using a small commercial team…

Trytosaveabit

Jun 26 10:59

Sometimes! Nice!

$BioXcel Therapeutics (BTAI.US)$ Sometimes when the chart hold decent? It pays to hold a Day trade overnight! But only when the chart says so and even then it can be a risk if bad news comes overnight!

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

BTAI BioXcel Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target